1. Criteria for HNF1B analysis in patients with congenital abnormalities of kidney and urinary tract.
- Author
-
Raaijmakers, Anke, Corveleyn, Anniek, Devriendt, Koen, van Tienoven, Theun Pieter, Allegaert, Karel, Van Dyck, Mieke, van den Heuvel, Lambertus, Kuypers, Dirk, Claes, Kathleen, Mekahli, Djalila, and Levtchenko, Elena
- Subjects
- *
HEPATOCYTE nuclear factors , *HUMAN abnormalities , *KIDNEY diseases , *URINARY tract infections , *KIDNEY development , *PATIENTS - Abstract
Background. Congenital anomalies of kidneys and urinary tract (CAKUT) are the most predominant developmental disorders comprising ~20-30% of all anomalies identified in the prenatal period. Mutations in hepatocyte nuclear factor 1-beta (HNF-1ß) involved in the development of kidneys, liver, pancreas and urogenital tract are currently the most frequent monogenetic cause of CAKUT found in 10-30% of patients depending on screening policy and study design. We aimed to validate criteria for analysis of HNF1B in a prospective cohort of paediatric and adult CAKUT patients. Methods. We included CAKUT patients diagnosed in our paediatric and adult nephrology departments from January 2010 until April 2013 based on predefined screening criteria. Subjects presenting with at least one major renal criterion or one minor renal criterion combined with one or more extrarenal criteria in the personal history or a familial history of renal or extra-renal manifestations were considered eligible. Results. We prospectively screened 205 patients and detected HNF1B mutations in 10% [n = 20, 12 children, median age 4.2 (range 0-13.1) years and 8 adults, median age 34.8 (range 16.6-62) years]. We observed that bilateral renal anomaly, renal cysts from unknown origin, a combination of two major renal anomalies and hypomagnesaemia were predictive for finding HNF1B mutations (P < 0.001; P < 0.001; P = 0.004; P = 0.008, respectively). Conclusions. We demonstrated that HNF1B mutations are responsible for ~10% of CAKUT cases, both in children and in adults. Based on our results we propose adapted criteria for HNF1B analysis to reduce the screening costs without missing affected patients. These criteria should be reaffirmed in a larger validation cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF